Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 12:14 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 1,824 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Media Clear all

Conditions: Pancreatic Ductal Adenocarcinoma, Colorectal Adenocarcinoma, Gastric Adenocarcinoma, Clinical Stage II Gastric Cancer AJCC v8, Clinical Stage IIA Gastric Cancer AJCC v8, Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIB Gastric Cancer AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Malignant Solid Neoplasm, Pathologic Stage II Gastric Cancer AJCC v8, Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIB Gastric Cancer AJCC v8, Pathologic Stage III Esophageal Adenocarcinoma AJCC v8, Pathologic Stage III Gastric Cancer AJCC v8, Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastric Cancer AJCC v8, Pathologic Stage IIIB Gastric Cancer AJCC v8, Pathologic Stage IIIC Gastric Cancer AJCC v8, Stage I Pancreatic Cancer AJCC v8, Stage IA Pancreatic Cancer AJCC v8, Stage IB Pancreatic Cancer AJCC v8, Stage II Pancreatic Cancer AJCC v8, Stage IIA Pancreatic Cancer AJCC v8, Stage IIB Pancreatic Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Malignant Digestive System Neoplasm, Small Intestinal Adenocarcinoma, Stage III Small Intestinal Adenocarcinoma AJCC v8, Stage IIIA Small Intestinal Adenocarcinoma AJCC v8, Minimal Residual Disease
Interventions: Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE; Biological
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Refractory Cancer, Metastatic Cancer, Recurrent Cancer, Unresectable Carcinoma, Solid Tumor, Adult, Advanced Cancer, Advanced Solid Tumor
Interventions: SNK01, Avelumab, Pembrolizumab; Biological · Drug
Lead sponsor: NKGen Biotech, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Healthy, Self Esteem, Self Efficacy, Knowledge
Interventions: radKIDS2.0 Safety and Empowerment Education Program; Behavioral
Lead sponsor: Saavsus, Inc.; Other
Eligibility: 9 Years to 75 Years
Enrollment: 656 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Eugene, Oregon • Springfield, Oregon

Conditions: Cancer, Cancer Metastatic, Neoplasms, Breast Cancer, Lung Cancer, Thyroid Cancer, Lymphoma, Lymphoma, Non-Hodgkin, Hodgkin Lymphoma, Leukemia, Sarcoma, Skin Cancer, Bone Cancer, Gynecologic Cancer, Pancreas Cancer, Multiple Myeloma, Colorectal Cancer, Gastrointestinal Cancer, Prostate Cancer, Glioblastoma, Brain Cancer, Head and Neck Cancer
Interventions: Virtual group based physical activity (BurnAlong) and Social Media Discussion Board; Behavioral
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 39 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Geographic Atrophy
Interventions: OCU410; Genetic
Lead sponsor: Ocugen; Industry
Eligibility: 50 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 12
States / cities: Phoenix, Arizona • Coral Springs, Florida • Carmel, Indiana + 9 more

Conditions: Dermatitis, Atopic
Interventions: Dupilumab, Matching Placebo, Background Treatment: Topical Corticosteroids, Background Treatment: Moisturizers; Drug · Other
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 367 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 31
States / cities: Birmingham, Alabama • Gilbert, Arizona • Bakersfield, California + 27 more

Conditions: Neoplasms
Interventions: BI 754091; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 7
States / cities: Sarasota, Florida • Harvey, Illinois • Detroit, Michigan + 4 more

Conditions: Cancer
Interventions: Psilocybin; Drug
Lead sponsor: University of Utah; Other
Eligibility: 25 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Intracerebral Hemorrhage
Interventions: Albumin, Placebo, Brain MRI with and without contrast; Drug · Procedure
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Radiographic Axial Spondyloarthritis
Interventions: Tulisokibart, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 37
States / cities: Chandler, Arizona • Flagstaff, Arizona • Gilbert, Arizona + 33 more

Conditions: Healthy
Interventions: Transcranial Focused Ultrasound; Device
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 22 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Thrombocytopenia
Interventions: Medium Dose Prophylactic Platelet Transfusions, Lower Dose Prophylactic Platelet Transfusions, Higher Dose Prophylactic Platelet Transfusions; Procedure
Lead sponsor: Carelon Research; Other
Eligibility: Up to 100 Years
Enrollment: 1,351 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 21
States / cities: Atlanta, Georgia • Iowa City, Iowa • New Orleans, Louisiana + 14 more

Conditions: Cervical Dystonia
Interventions: ABP-450, Placebo; Drug
Lead sponsor: AEON Biopharma, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 21
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Fountain Valley, California + 17 more

Conditions: Influenza, COVID-19, Communication Research, Health Behavior, Respiratory Viral Infection
Interventions: Science Communication Curriculum Cohort 1, Science communication curriculum Cohort 2, Science communication curriculum Cohort 3, Science communication curriculum Cohort 4; Behavioral
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 99 Years
Enrollment: 1,400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2029
U.S. locations: 4
States / cities: Chicago, Illinois • Iowa City, Iowa • Ann Arbor, Michigan

Conditions: Engagement, Patient, Quality of Life, Mood, Aging Well, Cognitive Change, Mild Cognitive Impairment, Cognitive Impairment, Dementia
Interventions: Behavioral Interventions, Robot Interventions; Behavioral
Lead sponsor: SimpleC, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Athens, Georgia • Atlanta, Georgia

Conditions: HIV
Interventions: Standard of Care, FemAALES; Behavioral
Lead sponsor: Charles Drew University of Medicine and Science; Other
Eligibility: 18 Years to 54 Years · Female only
Enrollment: 256 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2018
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Tobacco Use Cessation
Interventions: Nicotine Patch, Questionnaires, Pamphlet, Phone Counseling Sessions, Saliva Test, Smart phone; Drug · Behavioral · Other + 1 more
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prostate Carcinoma
Interventions: Media Intervention, Survey Administration; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 35 Years to 70 Years · Male only
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Physical Activity
Interventions: SMART Behavioral Group, SMART Informational Group; Behavioral
Lead sponsor: University of Illinois at Urbana-Champaign; Other
Eligibility: 13 Years to 15 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Urbana, Illinois

Conditions: Infertility, Pregnancy Outcome, Live Birth, In Vitro Fertilization
Interventions: 10% SSS embryo culture medium protein supplementation, 0.5% HSA embryo culture medium protein supplementation; Other
Lead sponsor: Texas Health Resources; Other
Eligibility: 20 Years to 40 Years · Female only
Enrollment: 538 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 2
States / cities: Dallas, Texas • Plano, Texas

Conditions: Cardiovascular Disease, Cigarette Smoking
Interventions: Subject's usual brand (UB) tobacco product; Other
Lead sponsor: R.J. Reynolds Tobacco Company; Industry
Eligibility: 26 Years to 49 Years · Male only
Enrollment: 168 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Mesenchymal Stromal Cells, Cornea, Safety, Corneal Defect
Interventions: Allogeneic MSC; Biological
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 4
States / cities: Chicago, Illinois • Baltimore, Maryland • Boston, Massachusetts + 1 more

Conditions: Control Group, Social Media
Interventions: Effects of Instagram Exposure on Lifestyle Satisfaction; Behavioral
Lead sponsor: Arizona State University; Other
Eligibility: 18 Years to 29 Years · Female only
Enrollment: 98 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Psoriasis
Interventions: peficitinib, Placebo; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 11
States / cities: Birmingham, Alabama • San Diego, California • Miami, Florida + 8 more

Search by objective public record fields.

A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma

Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy

Evaluation of radKIDS 2.0, a Multi-media Training Program for Elementary School Bullying and Abuse Prevention

The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors

Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy

Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)

A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours

Study of Psilocybin Enhanced Group Psychotherapy in Patients With Cancer

Albumin for Intracerebral Hemorrhage Intervention

A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)

Safety Assessment of Central Medial Thalamus Stimulation Using Transcranial Focused Ultrasound

Optimal Platelet Dose Strategy for Management of Thrombocytopenia

A Phase 2 Study to Evaluate the Safety and Efficacy of ABP-450 in the Treatment of Cervical Dystonia

Dime La VerDAD: Verify, Debunk, and Disseminate

SimpleC Wellness Platform With Social Robot Interaction (Long-term)

Females of African American Legacy Empowering Self (FemAALES)

Mobile Media-Rich Interactive Guideline System (MMRIGS) Pilot Study

Assessment of Research Digest Impact for Minority with Prostate Cancer, MiCAP Phase III Study

The Social Media and Activity Research in Teens Trial

in Vitro Fertilization (IVF) Media Protein and Live Birth Rates

Cardiovascular Disease Biomarkers in Smokers and Moist Snuff Consumers

Safety of Locally Delivered Allogeneic Mesenchymal Stromal Cells

Social Media Effects on Lifestyle Satisfaction

A Study to Explore Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Psoriasis